Brainsway (BWAY) CFO discloses initial share, RSU and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Brainsway Ltd. chief financial officer Ido Marom filed an initial ownership report showing his equity stake in the company. He directly holds 51,250 Ordinary Shares, a figure that includes unvested restricted stock units that will vest in scheduled quarterly installments through dates extending to March 2030.
Marom also holds stock options over 46,875 Ordinary Shares granted in August 2023 and 17,500 Ordinary Shares granted in March 2024, both vesting in equal quarterly installments through 2027 and 2028, with exercise prices of NIS 4.28 and NIS 11.17 per share, respectively. This filing records existing holdings rather than new market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Marom Ido
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Options (right to buy) | -- | -- | -- |
| holding | Stock Options (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Stock Options (right to buy) — 46,875 shares (Direct);
Ordinary Shares — 51,250 shares (Direct)
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. This figure includes unvested restricted stock units ("RSUs"), with each RSU representing a contingent right to receive one ordinary share, as follows: (a) RSUs to receive 8,750 ordinary shares vesting in equal quarterly installments until March 5, 2028, (b) RSUs to receive 10,000 ordinary shares with 2,500 vesting on November 10, 2026 and the remainder vesting in equal quarterly installments until November 10, 2029, and (c) RSUs to receive 32,500 ordinary shares with 8,125 vesting on March 10, 2027 and the remainder vesting in equal quarterly installments until March 10, 2030. Stock options were granted on August 8, 2023, with the remaining options to purchase 46,875 ordinary shares vesting in equal quarterly installments until May 18, 2027. The exercise price is NIS 4.28 per share. Stock options were granted on March 5, 2024, with the remaining options to purchase 17,500 ordinary shares vesting in equal quarterly installments until March 5, 2028. The exercise price is NIS 11.17 per share.
FAQ
What does Brainsway (BWAY) CFO Ido Marom report on this Form 3?
Ido Marom reports his initial ownership in Brainsway, including 51,250 Ordinary Shares and multiple equity awards. These positions reflect his existing stake and compensation structure rather than new open‑market transactions or recent share purchases or sales.
What stock options does the Brainsway (BWAY) CFO have outstanding?
The CFO holds stock options granted in August 2023 for 46,875 Ordinary Shares and in March 2024 for 17,500 Ordinary Shares. Both grants vest in equal quarterly installments into 2027 and 2028, with exercise prices of NIS 4.28 and NIS 11.17 per share.
Are the Brainsway (BWAY) CFO’s equity awards in the Form 3 already vested?
Many of the CFO’s awards are unvested and vest over time. The RSUs and stock options vest in equal quarterly installments on schedules running to 2027, 2028, 2029, and 2030, aligning his compensation with longer‑term company performance.